Literature DB >> 22371889

In vivo selection of moxifloxacin-resistant Clostridium difficile.

Ana Mena, Elena Riera, Carla López-Causapé, Irene Weber, José L Pérez, Antonio Oliver.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22371889      PMCID： PMC3346592          DOI： 10.1128/AAC.06433-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  16 in total

Review 1.  Detection of Clostridium difficile infection.

Authors:  John G Bartlett
Journal:  Infect Control Hosp Epidemiol       Date:  2010-11       Impact factor: 3.254

2.  A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality.

Authors:  Vivian G Loo; Louise Poirier; Mark A Miller; Matthew Oughton; Michael D Libman; Sophie Michaud; Anne-Marie Bourgault; Tuyen Nguyen; Charles Frenette; Mirabelle Kelly; Anne Vibien; Paul Brassard; Susan Fenn; Ken Dewar; Thomas J Hudson; Ruth Horn; Pierre René; Yury Monczak; André Dascal
Journal:  N Engl J Med       Date:  2005-12-01       Impact factor: 91.245

3.  An epidemic, toxin gene-variant strain of Clostridium difficile.

Authors:  L Clifford McDonald; George E Killgore; Angela Thompson; Robert C Owens; Sophia V Kazakova; Susan P Sambol; Stuart Johnson; Dale N Gerding
Journal:  N Engl J Med       Date:  2005-12-01       Impact factor: 91.245

4.  Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec.

Authors:  Jacques Pépin; Nathalie Saheb; Marie-Andrée Coulombe; Marie-Eve Alary; Marie-Pier Corriveau; Simon Authier; Michel Leblanc; Geneviève Rivard; Mathieu Bettez; Valérie Primeau; Martin Nguyen; Claude-Emilie Jacob; Luc Lanthier
Journal:  Clin Infect Dis       Date:  2005-09-20       Impact factor: 9.079

5.  High-level resistance to moxifloxacin and gatifloxacin associated with a novel mutation in gyrB in toxin-A-negative, toxin-B-positive Clostridium difficile.

Authors:  Denise Drudy; Teresa Quinn; Rebecca O'Mahony; Lorraine Kyne; Peadar O'Gaora; Séamus Fanning
Journal:  J Antimicrob Chemother       Date:  2006-10-03       Impact factor: 5.790

6.  A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use.

Authors:  Carlene A Muto; Marian Pokrywka; Kathleen Shutt; Aaron B Mendelsohn; Kathy Nouri; Kathy Posey; Terri Roberts; Karen Croyle; Sharon Krystofiak; Sujata Patel-Brown; A William Pasculle; David L Paterson; Melissa Saul; Lee H Harrison
Journal:  Infect Control Hosp Epidemiol       Date:  2005-03       Impact factor: 3.254

7.  Development of a new PCR-ribotyping method for Clostridium difficile based on ribosomal RNA gene sequencing.

Authors:  P Bidet; F Barbut; V Lalande; B Burghoffer; J C Petit
Journal:  FEMS Microbiol Lett       Date:  1999-06-15       Impact factor: 2.742

8.  gyrA and gyrB mutations are implicated in cross-resistance to Ciprofloxacin and moxifloxacin in Clostridium difficile.

Authors:  Larbi Dridi; Jacques Tankovic; Béatrice Burghoffer; Frédéric Barbut; Jean-Claude Petit
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

9.  Moxifloxacin therapy as a risk factor for Clostridium difficile-associated disease during an outbreak: attempts to control a new epidemic strain.

Authors:  Priscilla Biller; Beth Shank; Leah Lind; Meghan Brennan; Lisa Tkatch; George Killgore; Angela Thompson; L Clifford McDonald
Journal:  Infect Control Hosp Epidemiol       Date:  2007-01-25       Impact factor: 3.254

10.  gyrA mutations in fluoroquinolone-resistant Clostridium difficile PCR-027.

Authors:  Denise Drudy; Lorraine Kyne; Rebecca O'Mahony; Séamus Fanning
Journal:  Emerg Infect Dis       Date:  2007-03       Impact factor: 6.883
View more
  2 in total

1.  In vivo selection of rifamycin-resistant Clostridium difficile during rifaximin therapy.

Authors:  Robert J Carman; James H Boone; Harish Grover; Kimberly N Wickham; Li Chen
Journal:  Antimicrob Agents Chemother       Date:  2012-08-20       Impact factor: 5.191

Review 2.  Antimicrobial Resistance and Reduced Susceptibility in Clostridium difficile: Potential Consequences for Induction, Treatment, and Recurrence of C. difficile Infection.

Authors:  Simon D Baines; Mark H Wilcox
Journal:  Antibiotics (Basel)       Date:  2015-07-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.